Context and Menarini to trial combination in breast cancer

Context Therapeutics (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and Italy's family-owned Menarini Group have announced a clinical trial collaboration and supply agreement for the latter firm's oral selective estrogen receptor degrader, elacestrant.

Following the announcement, Context's share price was 13% higher in Tuesday's early afternoon trading in New York.

This agreement will support the upcoming Phase Ib/II ELONA clinical proof-of-concept trial evaluating Context's lead candidate onapristone extended release, an oral progesterone receptor (PR) antagonist, in combination with elacestrant in estrogen receptor positive (ER+), PR+ HER2- metastatic breast cancer (mBC) patients who have previously been treated with a CDK4/6 inhibitor.